AIP (AHR Interacting Protein) is a co-chaperone protein that functions as a negative regulator of cellular signaling and lipid metabolism. Mechanistically, AIP interacts with the Aryl Hydrocarbon Receptor (AHR) and phosphodiesterases (PDE4A5 and PDE2A3) to modulate cAMP signaling pathways 1. In macrophages, AIP suppresses cholesterol-ester accumulation by inhibiting p38-c-JUN-mediated HM13/SPP transactivation via its AHR-chaperone interaction, thereby preventing foamy macrophage formation and reducing atherogenesis 2. Clinically, AIP mutations are associated with familial isolated pituitary adenoma (FIPA), accounting for approximately 20% of cases, typically presenting as somatotropinomas causing gigantism or young-onset acromegaly 1. The tumor suppressor properties of AIP in somatotroph cells involve negative regulation of cAMP signaling. Loss-of-function AIP mutations impair these protective mechanisms, predisposing to pituitary adenoma development. Genetic evaluation of AIP variants through AIP-PDE4A5 interaction studies enhances pathogenicity assessment and enables prospective adenoma diagnosis in mutation carriers, guiding clinical screening and genetic counseling strategies.